Overview

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

This is a prospective, open controlled trial in which naïve HIV-1 patients will be randomized to receive atazanavir / ritonavir or darunavir / ritonavir in combination with tenofovir / emtricitabine. They will be followed up during 96 weeks to determinate the cholesterol levels. Randomization will be stratified according to the values of the ratio of total cholesterol/HDL cholesterol obtained during the screening visit (as they will be <4.5 or ≥ 4.5).

Phase:

Phase 4

Details

Lead Sponsor:

Juan A. Arnaiz

Treatments:

Atazanavir Sulfate
Darunavir
Emtricitabine
Ritonavir
Tenofovir